Search - tctmd.com

Displaying 741 - 760 of 2323

Sort: Relevancy | Date

Revascularization in Stable CAD: What Do the New 2019 ESC Guidelines Recommend?

Presentation TCT 2019

Revascularization in Stable CAD: What Do the New 2019 ESC Guidelines Recommend?

Presenter: Jean Fajadet

September 27, 2019

How Artificial Intelligence (AI) Will Change PCI

Presentation TCT 2019

How Artificial Intelligence (AI) Will Change PCI

Presenter: Javier Escaned

September 27, 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

September 26, 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Top Stories in Cardiology: August 2019

Podcast Heart Sounds

Top Stories in Cardiology: September 2019

September 25, 2019

CTO Crossing 1: Case Examples of Wire Escalation

Presentation TCT 2019

CTO Crossing 1: Case Examples of Wire Escalation

Presenter: Ethan Korngold

September 25, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

News Daily News

CMS Weighs Reimbursement for Out-of-Hospital Coronary Interventions

September 20, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

News Daily News

MI Definitions in SCOT-HEART Prompt Outcry—Then Silence—on Twitter

September 19, 2019

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

News Daily News

Polypill Drops BP, LDL Cholesterol in a Disadvantaged US Population

September 18, 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

News Conference News ESC 2019

Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients

September 13, 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

September 12, 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

September 10, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.